Upper urinary tract urothelial carcinoma with loco-regional nodal metastases

Insights from the Upper Tract Urothelial Carcinoma Collaboration

Ramy F. Youssef, Shahrokh F. Shariat, Yair Lotan, Christopher G. Wood, Arthur I. Sagalowsky, Richard Zigeuner, Eiji Kikuchi, Alon Weizer, Jay D. Raman, Mesut Remzi, Wareef Kabbani, Cord Langner, Charles C. Guo, Marco Roscigno, Francesco Montorsi, Christian Bolenz, Wassim Kassouf, Vitaly Margulis

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Study Type - Therapy (multi-insititutional cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Neoadjuvant chemotherapy offers survival benefits for patients with urothelial carcinoma of the bladder. However, it is still underutilized in the 'biologically similar' upper tract urothelial carcinoma. Systemic chemotherapy in a neoadjuvant setting is a more attractive option, as loss of renal function after nephrectomy can complicate the administration of adjuvant chemotherapy. We found that preoperative systemic therapy followed by aggressive surgical debulking is a promising treatment strategy for upper tract urothelial carcinoma patients with known or at risk of loco-regional nodal metastasis. OBJECTIVE • To describe a multicentre experience with preoperative platinum-based chemotherapy before radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC) with loco-regional nodal metastases. PATIENTS AND METHODS • We identified 313 patients from the UTUC Collaboration (over 1200 patients), who underwent RNU with concomitant retroperitoneal lymph node dissection between 1990 and 2007 and met the inclusion criteria for one of three groups. • Group 1 comprised patients who received chemotherapy before RNU because of biopsy-proven loco-regional nodal metastases. • Group 2 consisted of patients who underwent primary RNU and were found to have metastatic nodal disease on final pathological review (node-positive). • Group 3 comprised a comparative cohort of patients treated with primary RNU for invasive or locally advanced (pT2/pT4) node-negative (N0) UTUC. RESULTS • Groups 1, 2 and 3 included 18, 120 and 175 patients, respectively. The 5-year disease-free survival rates were 49%, 30% and 64%, whereas the 5-year cancer-specific survival rates were 44%, 36% and 69% in groups 1, 2 and 3, respectively. • In group 1, on final pathological evaluation, nine patients were pN0, six patients were pT0 and five patients had pT0N0 disease. Kaplan-Meier survival analyses showed similar recurrence and survival rates in group 1 compared with group 3 (P= 0.14 and P= 0.06, respectively). • Meanwhile, group 2 had significantly lower disease-free and cancer-specific survival rates compared with group 3 (P < 0.001 and P < 0.001, respectively) and compared with group 1 (P= 0.04 and P= 0.06, respectively). CONCLUSIONS • Preoperative chemotherapy followed by aggressive surgical consolidation may yield favourable oncological outcomes in patients with UTUC with loco-regional nodal metastases. • These data support further evaluation of neoadjuvant systemic therapy in patients at risk for locally advanced UTUC.

Original languageEnglish
Pages (from-to)1286-1291
Number of pages6
JournalBJU International
Volume108
Issue number8
DOIs
Publication statusPublished - 2011 Oct

Fingerprint

Urinary Tract
Neoplasm Metastasis
Carcinoma
Drug Therapy
Survival Rate
Neoadjuvant Therapy
Kaplan-Meier Estimate
Adjuvant Chemotherapy
Survival Analysis
Platinum
Lymph Node Excision
Nephrectomy
Disease-Free Survival
Neoplasms
Urinary Bladder
Therapeutics

Keywords

  • chemotherapy
  • lymph node metastases
  • urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Upper urinary tract urothelial carcinoma with loco-regional nodal metastases : Insights from the Upper Tract Urothelial Carcinoma Collaboration. / Youssef, Ramy F.; Shariat, Shahrokh F.; Lotan, Yair; Wood, Christopher G.; Sagalowsky, Arthur I.; Zigeuner, Richard; Kikuchi, Eiji; Weizer, Alon; Raman, Jay D.; Remzi, Mesut; Kabbani, Wareef; Langner, Cord; Guo, Charles C.; Roscigno, Marco; Montorsi, Francesco; Bolenz, Christian; Kassouf, Wassim; Margulis, Vitaly.

In: BJU International, Vol. 108, No. 8, 10.2011, p. 1286-1291.

Research output: Contribution to journalArticle

Youssef, RF, Shariat, SF, Lotan, Y, Wood, CG, Sagalowsky, AI, Zigeuner, R, Kikuchi, E, Weizer, A, Raman, JD, Remzi, M, Kabbani, W, Langner, C, Guo, CC, Roscigno, M, Montorsi, F, Bolenz, C, Kassouf, W & Margulis, V 2011, 'Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: Insights from the Upper Tract Urothelial Carcinoma Collaboration', BJU International, vol. 108, no. 8, pp. 1286-1291. https://doi.org/10.1111/j.1464-410X.2011.10075.x
Youssef, Ramy F. ; Shariat, Shahrokh F. ; Lotan, Yair ; Wood, Christopher G. ; Sagalowsky, Arthur I. ; Zigeuner, Richard ; Kikuchi, Eiji ; Weizer, Alon ; Raman, Jay D. ; Remzi, Mesut ; Kabbani, Wareef ; Langner, Cord ; Guo, Charles C. ; Roscigno, Marco ; Montorsi, Francesco ; Bolenz, Christian ; Kassouf, Wassim ; Margulis, Vitaly. / Upper urinary tract urothelial carcinoma with loco-regional nodal metastases : Insights from the Upper Tract Urothelial Carcinoma Collaboration. In: BJU International. 2011 ; Vol. 108, No. 8. pp. 1286-1291.
@article{4b44d01981e746e79ea4c33b670505b8,
title = "Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: Insights from the Upper Tract Urothelial Carcinoma Collaboration",
abstract = "Study Type - Therapy (multi-insititutional cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Neoadjuvant chemotherapy offers survival benefits for patients with urothelial carcinoma of the bladder. However, it is still underutilized in the 'biologically similar' upper tract urothelial carcinoma. Systemic chemotherapy in a neoadjuvant setting is a more attractive option, as loss of renal function after nephrectomy can complicate the administration of adjuvant chemotherapy. We found that preoperative systemic therapy followed by aggressive surgical debulking is a promising treatment strategy for upper tract urothelial carcinoma patients with known or at risk of loco-regional nodal metastasis. OBJECTIVE • To describe a multicentre experience with preoperative platinum-based chemotherapy before radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC) with loco-regional nodal metastases. PATIENTS AND METHODS • We identified 313 patients from the UTUC Collaboration (over 1200 patients), who underwent RNU with concomitant retroperitoneal lymph node dissection between 1990 and 2007 and met the inclusion criteria for one of three groups. • Group 1 comprised patients who received chemotherapy before RNU because of biopsy-proven loco-regional nodal metastases. • Group 2 consisted of patients who underwent primary RNU and were found to have metastatic nodal disease on final pathological review (node-positive). • Group 3 comprised a comparative cohort of patients treated with primary RNU for invasive or locally advanced (pT2/pT4) node-negative (N0) UTUC. RESULTS • Groups 1, 2 and 3 included 18, 120 and 175 patients, respectively. The 5-year disease-free survival rates were 49{\%}, 30{\%} and 64{\%}, whereas the 5-year cancer-specific survival rates were 44{\%}, 36{\%} and 69{\%} in groups 1, 2 and 3, respectively. • In group 1, on final pathological evaluation, nine patients were pN0, six patients were pT0 and five patients had pT0N0 disease. Kaplan-Meier survival analyses showed similar recurrence and survival rates in group 1 compared with group 3 (P= 0.14 and P= 0.06, respectively). • Meanwhile, group 2 had significantly lower disease-free and cancer-specific survival rates compared with group 3 (P < 0.001 and P < 0.001, respectively) and compared with group 1 (P= 0.04 and P= 0.06, respectively). CONCLUSIONS • Preoperative chemotherapy followed by aggressive surgical consolidation may yield favourable oncological outcomes in patients with UTUC with loco-regional nodal metastases. • These data support further evaluation of neoadjuvant systemic therapy in patients at risk for locally advanced UTUC.",
keywords = "chemotherapy, lymph node metastases, urothelial carcinoma",
author = "Youssef, {Ramy F.} and Shariat, {Shahrokh F.} and Yair Lotan and Wood, {Christopher G.} and Sagalowsky, {Arthur I.} and Richard Zigeuner and Eiji Kikuchi and Alon Weizer and Raman, {Jay D.} and Mesut Remzi and Wareef Kabbani and Cord Langner and Guo, {Charles C.} and Marco Roscigno and Francesco Montorsi and Christian Bolenz and Wassim Kassouf and Vitaly Margulis",
year = "2011",
month = "10",
doi = "10.1111/j.1464-410X.2011.10075.x",
language = "English",
volume = "108",
pages = "1286--1291",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Upper urinary tract urothelial carcinoma with loco-regional nodal metastases

T2 - Insights from the Upper Tract Urothelial Carcinoma Collaboration

AU - Youssef, Ramy F.

AU - Shariat, Shahrokh F.

AU - Lotan, Yair

AU - Wood, Christopher G.

AU - Sagalowsky, Arthur I.

AU - Zigeuner, Richard

AU - Kikuchi, Eiji

AU - Weizer, Alon

AU - Raman, Jay D.

AU - Remzi, Mesut

AU - Kabbani, Wareef

AU - Langner, Cord

AU - Guo, Charles C.

AU - Roscigno, Marco

AU - Montorsi, Francesco

AU - Bolenz, Christian

AU - Kassouf, Wassim

AU - Margulis, Vitaly

PY - 2011/10

Y1 - 2011/10

N2 - Study Type - Therapy (multi-insititutional cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Neoadjuvant chemotherapy offers survival benefits for patients with urothelial carcinoma of the bladder. However, it is still underutilized in the 'biologically similar' upper tract urothelial carcinoma. Systemic chemotherapy in a neoadjuvant setting is a more attractive option, as loss of renal function after nephrectomy can complicate the administration of adjuvant chemotherapy. We found that preoperative systemic therapy followed by aggressive surgical debulking is a promising treatment strategy for upper tract urothelial carcinoma patients with known or at risk of loco-regional nodal metastasis. OBJECTIVE • To describe a multicentre experience with preoperative platinum-based chemotherapy before radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC) with loco-regional nodal metastases. PATIENTS AND METHODS • We identified 313 patients from the UTUC Collaboration (over 1200 patients), who underwent RNU with concomitant retroperitoneal lymph node dissection between 1990 and 2007 and met the inclusion criteria for one of three groups. • Group 1 comprised patients who received chemotherapy before RNU because of biopsy-proven loco-regional nodal metastases. • Group 2 consisted of patients who underwent primary RNU and were found to have metastatic nodal disease on final pathological review (node-positive). • Group 3 comprised a comparative cohort of patients treated with primary RNU for invasive or locally advanced (pT2/pT4) node-negative (N0) UTUC. RESULTS • Groups 1, 2 and 3 included 18, 120 and 175 patients, respectively. The 5-year disease-free survival rates were 49%, 30% and 64%, whereas the 5-year cancer-specific survival rates were 44%, 36% and 69% in groups 1, 2 and 3, respectively. • In group 1, on final pathological evaluation, nine patients were pN0, six patients were pT0 and five patients had pT0N0 disease. Kaplan-Meier survival analyses showed similar recurrence and survival rates in group 1 compared with group 3 (P= 0.14 and P= 0.06, respectively). • Meanwhile, group 2 had significantly lower disease-free and cancer-specific survival rates compared with group 3 (P < 0.001 and P < 0.001, respectively) and compared with group 1 (P= 0.04 and P= 0.06, respectively). CONCLUSIONS • Preoperative chemotherapy followed by aggressive surgical consolidation may yield favourable oncological outcomes in patients with UTUC with loco-regional nodal metastases. • These data support further evaluation of neoadjuvant systemic therapy in patients at risk for locally advanced UTUC.

AB - Study Type - Therapy (multi-insititutional cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Neoadjuvant chemotherapy offers survival benefits for patients with urothelial carcinoma of the bladder. However, it is still underutilized in the 'biologically similar' upper tract urothelial carcinoma. Systemic chemotherapy in a neoadjuvant setting is a more attractive option, as loss of renal function after nephrectomy can complicate the administration of adjuvant chemotherapy. We found that preoperative systemic therapy followed by aggressive surgical debulking is a promising treatment strategy for upper tract urothelial carcinoma patients with known or at risk of loco-regional nodal metastasis. OBJECTIVE • To describe a multicentre experience with preoperative platinum-based chemotherapy before radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC) with loco-regional nodal metastases. PATIENTS AND METHODS • We identified 313 patients from the UTUC Collaboration (over 1200 patients), who underwent RNU with concomitant retroperitoneal lymph node dissection between 1990 and 2007 and met the inclusion criteria for one of three groups. • Group 1 comprised patients who received chemotherapy before RNU because of biopsy-proven loco-regional nodal metastases. • Group 2 consisted of patients who underwent primary RNU and were found to have metastatic nodal disease on final pathological review (node-positive). • Group 3 comprised a comparative cohort of patients treated with primary RNU for invasive or locally advanced (pT2/pT4) node-negative (N0) UTUC. RESULTS • Groups 1, 2 and 3 included 18, 120 and 175 patients, respectively. The 5-year disease-free survival rates were 49%, 30% and 64%, whereas the 5-year cancer-specific survival rates were 44%, 36% and 69% in groups 1, 2 and 3, respectively. • In group 1, on final pathological evaluation, nine patients were pN0, six patients were pT0 and five patients had pT0N0 disease. Kaplan-Meier survival analyses showed similar recurrence and survival rates in group 1 compared with group 3 (P= 0.14 and P= 0.06, respectively). • Meanwhile, group 2 had significantly lower disease-free and cancer-specific survival rates compared with group 3 (P < 0.001 and P < 0.001, respectively) and compared with group 1 (P= 0.04 and P= 0.06, respectively). CONCLUSIONS • Preoperative chemotherapy followed by aggressive surgical consolidation may yield favourable oncological outcomes in patients with UTUC with loco-regional nodal metastases. • These data support further evaluation of neoadjuvant systemic therapy in patients at risk for locally advanced UTUC.

KW - chemotherapy

KW - lymph node metastases

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=80053020905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053020905&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2011.10075.x

DO - 10.1111/j.1464-410X.2011.10075.x

M3 - Article

VL - 108

SP - 1286

EP - 1291

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 8

ER -